My ePortfolio Register   

SIOG 2016 /
Abiraterone vs docetaxel for metastatic castrate resistant prostate cancer

17th - 19th Nov 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.16
Views: 346

Dr Shabbir Alibhai - Princess Margaret Cancer Centre, Toronto, Canada

Dr Alibhai speaks with ecancertv at SIOG 2016 about the experience of men receiving abiraterone or docetaxel for the treatment of metastatic castrate resistant prostate cancer. 

He discusses how the efficacy was similar to prior published studies, and how toxicities were slightly greater.

This service has been kindly supported by an unrestricted grant from Merck/MSD.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence